Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Myasthenia Gravis Drugs Market 2018, Forecast to 2023

January 2019 | 151 pages | ID: GBE6EBA21F6EN
GlobalInfoResearch

Abstracts

Acetylcholine esterase (AChE) inhibitors are considered to be the basic treatment of myasthenia gravis (MG). Edrophonium is primarily used as a diagnostic tool owing to its short half-life. Pyridostigmine is used for long-term maintenance.

Scope of the Report:

This report focuses on the Myasthenia Gravis Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The market is witnessing the rapid development of novel drugs such as monoclonal antibodies, which is one of the primary factors driving this market’s growth prospects. Most drug manufacturers are increasingly focussing on the development of monoclonal antibodies, as they act specifically on target cells; thereby, leading to lower side effects. Since conventional therapies such as acetylcholinesterase inhibitor, oral steroids, and immunomodulatory agents are associated with more side effects, physicians prefer to prescribe high efficacious monoclonal antibodies.
The worldwide market for Myasthenia Gravis Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

• Flamel Technologies
• Roche
• Grifols
• Pfizer
• Shire
• Novartis
• Valeant
• Alexion
• Catalyst
• CSL
• Curavac
• Cytokinetics
• Galencia
• GlaxoSmithKline
• Lupin Pharmaceuticals
• Mitsubishi Tanabe Pharma

Market Segment by Regions, regional analysis covers

• North America (United States, Canada and Mexico)
• Europe (Germany, France, UK, Russia and Italy)
• Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
• South America (Brazil, Argentina, Colombia etc.)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

• Anticholinesterases
• Immunosuppressants
• Intravenous Immune Globulins

Market Segment by Applications, can be divided into

• Hospitals
• Clinics

There are 15 Chapters to deeply display the global Myasthenia Gravis Drugs market.

Chapter 1, to describe Myasthenia Gravis Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Myasthenia Gravis Drugs, with sales, revenue, and price of Myasthenia Gravis Drugs, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Myasthenia Gravis Drugs, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Myasthenia Gravis Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Myasthenia Gravis Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Contents

1 MARKET OVERVIEW

1.1 Myasthenia Gravis Drugs Introduction
1.2 Market Analysis by Type
  1.2.1 Anticholinesterases
  1.2.2 Immunosuppressants
  1.2.3 Intravenous Immune Globulins
1.3 Market Analysis by Applications
  1.3.1 Hospitals
  1.3.2 Clinics
1.4 Market Analysis by Regions
  1.4.1 North America (United States, Canada and Mexico)
    1.4.1.1 United States Market States and Outlook (2013-2023)
    1.4.1.2 Canada Market States and Outlook (2013-2023)
    1.4.1.3 Mexico Market States and Outlook (2013-2023)
  1.4.2 Europe (Germany, France, UK, Russia and Italy)
    1.4.2.1 Germany Market States and Outlook (2013-2023)
    1.4.2.2 France Market States and Outlook (2013-2023)
    1.4.2.3 UK Market States and Outlook (2013-2023)
    1.4.2.4 Russia Market States and Outlook (2013-2023)
    1.4.2.5 Italy Market States and Outlook (2013-2023)
  1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
    1.4.3.1 China Market States and Outlook (2013-2023)
    1.4.3.2 Japan Market States and Outlook (2013-2023)
    1.4.3.3 Korea Market States and Outlook (2013-2023)
    1.4.3.4 India Market States and Outlook (2013-2023)
    1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
  1.4.4 South America, Middle East and Africa
    1.4.4.1 Brazil Market States and Outlook (2013-2023)
    1.4.4.2 Egypt Market States and Outlook (2013-2023)
    1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
    1.4.4.4 South Africa Market States and Outlook (2013-2023)
    1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
  1.5.1 Market Opportunities
  1.5.2 Market Risk
  1.5.3 Market Driving Force

2 MANUFACTURERS PROFILES

2.1 Flamel Technologies
  2.1.1 Business Overview
    2.1.1.1 Flamel Technologies Description
    2.1.1.2 Flamel Technologies Headquarter, Main Business and Finance Overview
  2.1.2 Flamel Technologies Myasthenia Gravis Drugs Product Introduction
    2.1.2.1 Myasthenia Gravis Drugs Production Bases, Sales Regions and Major Competitors
    2.1.2.2 Myasthenia Gravis Drugs Product Information
  2.1.3 Flamel Technologies Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.1.3.1 Flamel Technologies Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.1.3.2 Global Flamel Technologies Myasthenia Gravis Drugs Market Share in 2017
2.2 Roche
  2.2.1 Business Overview
    2.2.1.1 Roche Description
    2.2.1.2 Roche Headquarter, Main Business and Finance Overview
  2.2.2 Roche Myasthenia Gravis Drugs Product Introduction
    2.2.2.1 Myasthenia Gravis Drugs Production Bases, Sales Regions and Major Competitors
    2.2.2.2 Myasthenia Gravis Drugs Product Information
  2.2.3 Roche Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.2.3.1 Roche Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.2.3.2 Global Roche Myasthenia Gravis Drugs Market Share in 2017
2.3 Grifols
  2.3.1 Business Overview
    2.3.1.1 Grifols Description
    2.3.1.2 Grifols Headquarter, Main Business and Finance Overview
  2.3.2 Grifols Myasthenia Gravis Drugs Product Introduction
    2.3.2.1 Myasthenia Gravis Drugs Production Bases, Sales Regions and Major Competitors
    2.3.2.2 Myasthenia Gravis Drugs Product Information
  2.3.3 Grifols Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.3.3.1 Grifols Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.3.3.2 Global Grifols Myasthenia Gravis Drugs Market Share in 2017
2.4 Pfizer
  2.4.1 Business Overview
    2.4.1.1 Pfizer Description
    2.4.1.2 Pfizer Headquarter, Main Business and Finance Overview
  2.4.2 Pfizer Myasthenia Gravis Drugs Product Introduction
    2.4.2.1 Myasthenia Gravis Drugs Production Bases, Sales Regions and Major Competitors
    2.4.2.2 Myasthenia Gravis Drugs Product Information
  2.4.3 Pfizer Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.4.3.1 Pfizer Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.4.3.2 Global Pfizer Myasthenia Gravis Drugs Market Share in 2017
2.5 Shire
  2.5.1 Business Overview
    2.5.1.1 Shire Description
    2.5.1.2 Shire Headquarter, Main Business and Finance Overview
  2.5.2 Shire Myasthenia Gravis Drugs Product Introduction
    2.5.2.1 Myasthenia Gravis Drugs Production Bases, Sales Regions and Major Competitors
    2.5.2.2 Myasthenia Gravis Drugs Product Information
  2.5.3 Shire Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.5.3.1 Shire Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.5.3.2 Global Shire Myasthenia Gravis Drugs Market Share in 2017
2.6 Novartis
  2.6.1 Business Overview
    2.6.1.1 Novartis Description
    2.6.1.2 Novartis Headquarter, Main Business and Finance Overview
  2.6.2 Novartis Myasthenia Gravis Drugs Product Introduction
    2.6.2.1 Myasthenia Gravis Drugs Production Bases, Sales Regions and Major Competitors
    2.6.2.2 Myasthenia Gravis Drugs Product Information
  2.6.3 Novartis Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.6.3.1 Novartis Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.6.3.2 Global Novartis Myasthenia Gravis Drugs Market Share in 2017
2.7 Valeant
  2.7.1 Business Overview
    2.7.1.1 Valeant Description
    2.7.1.2 Valeant Headquarter, Main Business and Finance Overview
  2.7.2 Valeant Myasthenia Gravis Drugs Product Introduction
    2.7.2.1 Myasthenia Gravis Drugs Production Bases, Sales Regions and Major Competitors
    2.7.2.2 Myasthenia Gravis Drugs Product Information
  2.7.3 Valeant Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.7.3.1 Valeant Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.7.3.2 Global Valeant Myasthenia Gravis Drugs Market Share in 2017
2.8 Alexion
  2.8.1 Business Overview
    2.8.1.1 Alexion Description
    2.8.1.2 Alexion Headquarter, Main Business and Finance Overview
  2.8.2 Alexion Myasthenia Gravis Drugs Product Introduction
    2.8.2.1 Myasthenia Gravis Drugs Production Bases, Sales Regions and Major Competitors
    2.8.2.2 Myasthenia Gravis Drugs Product Information
  2.8.3 Alexion Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.8.3.1 Alexion Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.8.3.2 Global Alexion Myasthenia Gravis Drugs Market Share in 2017
2.9 Catalyst
  2.9.1 Business Overview
    2.9.1.1 Catalyst Description
    2.9.1.2 Catalyst Headquarter, Main Business and Finance Overview
  2.9.2 Catalyst Myasthenia Gravis Drugs Product Introduction
    2.9.2.1 Myasthenia Gravis Drugs Production Bases, Sales Regions and Major Competitors
    2.9.2.2 Myasthenia Gravis Drugs Product Information
  2.9.3 Catalyst Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.9.3.1 Catalyst Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.9.3.2 Global Catalyst Myasthenia Gravis Drugs Market Share in 2017
2.10 CSL
  2.10.1 Business Overview
    2.10.1.1 CSL Description
    2.10.1.2 CSL Headquarter, Main Business and Finance Overview
  2.10.2 CSL Myasthenia Gravis Drugs Product Introduction
    2.10.2.1 Myasthenia Gravis Drugs Production Bases, Sales Regions and Major Competitors
    2.10.2.2 Myasthenia Gravis Drugs Product Information
  2.10.3 CSL Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.10.3.1 CSL Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.10.3.2 Global CSL Myasthenia Gravis Drugs Market Share in 2017
2.11 Curavac
  2.11.1 Business Overview
  2.11.2 Curavac Myasthenia Gravis Drugs Product Introduction
  2.11.3 Curavac Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 Cytokinetics
  2.12.1 Business Overview
  2.12.2 Cytokinetics Myasthenia Gravis Drugs Product Introduction
  2.12.3 Cytokinetics Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 Galencia
  2.13.1 Business Overview
  2.13.2 Galencia Myasthenia Gravis Drugs Product Introduction
  2.13.3 Galencia Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.14 GlaxoSmithKline
  2.14.1 Business Overview
  2.14.2 GlaxoSmithKline Myasthenia Gravis Drugs Product Introduction
  2.14.3 GlaxoSmithKline Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.15 Lupin Pharmaceuticals
  2.15.1 Business Overview
  2.15.2 Lupin Pharmaceuticals Myasthenia Gravis Drugs Product Introduction
  2.15.3 Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.16 Mitsubishi Tanabe Pharma
  2.16.1 Business Overview
  2.16.2 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Product Introduction
  2.16.3 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 GLOBAL MYASTHENIA GRAVIS DRUGS MARKET COMPETITION, BY MANUFACTURER

3.1 Global Myasthenia Gravis Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Myasthenia Gravis Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Global Myasthenia Gravis Drugs Price by Manufacturer (2016-2017)
3.4 Market Concentration Rate
  3.4.1 Top 3 Myasthenia Gravis Drugs Manufacturer Market Share in 2017
  3.4.2 Top 5 Myasthenia Gravis Drugs Manufacturer Market Share in 2017
3.5 Market Competition Trend

4 GLOBAL MYASTHENIA GRAVIS DRUGS MARKET ANALYSIS BY REGIONS

4.1 Global Myasthenia Gravis Drugs Sales, Revenue and Market Share by Regions
  4.1.1 Global Myasthenia Gravis Drugs Sales by Regions (2013-2018)
  4.1.2 Global Myasthenia Gravis Drugs Revenue by Regions (2013-2018)
4.2 North America Myasthenia Gravis Drugs Sales, Revenue and Growth Rate (2013-2018)
4.3 Europe Myasthenia Gravis Drugs Sales, Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Myasthenia Gravis Drugs Sales, Revenue and Growth Rate (2013-2018)
4.5 South America Myasthenia Gravis Drugs Sales, Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Myasthenia Gravis Drugs Sales, Revenue and Growth Rate (2013-2018)

5 NORTH AMERICA MYASTHENIA GRAVIS DRUGS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS

5.1 North America Myasthenia Gravis Drugs Sales, Revenue and Market Share by Countries
  5.1.1 North America Myasthenia Gravis Drugs Sales by Countries (2013-2018)
  5.1.2 North America Myasthenia Gravis Drugs Revenue by Countries (2013-2018)
  5.1.3 United States Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
  5.1.4 Canada Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
  5.1.5 Mexico Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
5.2 North America Myasthenia Gravis Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
  5.2.1 North America Myasthenia Gravis Drugs Sales by Manufacturers (2016-2017)
  5.2.2 North America Myasthenia Gravis Drugs Revenue by Manufacturers (2016-2017)
5.3 North America Myasthenia Gravis Drugs Sales, Revenue and Market Share by Type (2013-2018)
  5.3.1 North America Myasthenia Gravis Drugs Sales and Sales Share by Type (2013-2018)
  5.3.2 North America Myasthenia Gravis Drugs Revenue and Revenue Share by Type (2013-2018)
5.4 North America Myasthenia Gravis Drugs Sales, Revenue and Market Share by Application (2013-2018)
  5.4.1 North America Myasthenia Gravis Drugs Sales and Sales Share by Application (2013-2018)
  5.4.2 North America Myasthenia Gravis Drugs Revenue and Revenue Share by Application (2013-2018)

6 EUROPE MYASTHENIA GRAVIS DRUGS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS

6.1 Europe Myasthenia Gravis Drugs Sales, Revenue and Market Share by Countries
  6.1.1 Europe Myasthenia Gravis Drugs Sales by Countries (2013-2018)
  6.1.2 Europe Myasthenia Gravis Drugs Revenue by Countries (2013-2018)
  6.1.3 Germany Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
  6.1.4 UK Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
  6.1.5 France Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
  6.1.6 Russia Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
  6.1.7 Italy Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
6.2 Europe Myasthenia Gravis Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
  6.2.1 Europe Myasthenia Gravis Drugs Sales by Manufacturers (2016-2017)
  6.2.2 Europe Myasthenia Gravis Drugs Revenue by Manufacturers (2016-2017)
6.3 Europe Myasthenia Gravis Drugs Sales, Revenue and Market Share by Type (2013-2018)
  6.3.1 Europe Myasthenia Gravis Drugs Sales and Sales Share by Type (2013-2018)
  6.3.2 Europe Myasthenia Gravis Drugs Revenue and Revenue Share by Type (2013-2018)
6.4 Europe Myasthenia Gravis Drugs Sales, Revenue and Market Share by Application (2013-2018)
  6.4.1 Europe Myasthenia Gravis Drugs Sales and Sales Share by Application (2013-2018)
  6.4.2 Europe Myasthenia Gravis Drugs Revenue and Revenue Share by Application (2013-2018)

7 ASIA-PACIFIC MYASTHENIA GRAVIS DRUGS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS

7.1 Asia-Pacific Myasthenia Gravis Drugs Sales, Revenue and Market Share by Countries
  7.1.1 Asia-Pacific Myasthenia Gravis Drugs Sales by Countries (2013-2018)
  7.1.2 Asia-Pacific Myasthenia Gravis Drugs Revenue by Countries (2013-2018)
  7.1.3 China Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
  7.1.4 Japan Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
  7.1.5 Korea Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
  7.1.6 India Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
  7.1.7 Southeast Asia Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
7.2 Asia-Pacific Myasthenia Gravis Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
  7.2.1 Asia-Pacific Myasthenia Gravis Drugs Sales by Manufacturers (2016-2017)
  7.2.2 Asia-Pacific Myasthenia Gravis Drugs Revenue by Manufacturers (2016-2017)
7.3 Asia-Pacific Myasthenia Gravis Drugs Sales, Revenue and Market Share by Type (2013-2018)
  7.3.1 Asia-Pacific Myasthenia Gravis Drugs Sales and Sales Share by Type (2013-2018)
  7.3.2 Asia-Pacific Myasthenia Gravis Drugs Revenue and Revenue Share by Type (2013-2018)
7.4 Asia-Pacific Myasthenia Gravis Drugs Sales, Revenue and Market Share by Application (2013-2018)
  7.4.1 Asia-Pacific Myasthenia Gravis Drugs Sales and Sales Share by Application (2013-2018)
  7.4.2 Asia-Pacific Myasthenia Gravis Drugs Revenue and Revenue Share by Application (2013-2018)

8 SOUTH AMERICA MYASTHENIA GRAVIS DRUGS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS

8.1 South America Myasthenia Gravis Drugs Sales, Revenue and Market Share by Countries
  8.1.1 South America Myasthenia Gravis Drugs Sales by Countries (2013-2018)
  8.1.2 South America Myasthenia Gravis Drugs Revenue by Countries (2013-2018)
  8.1.3 Brazil Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
  8.1.4 Argentina Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
  8.1.5 Colombia Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
8.2 South America Myasthenia Gravis Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
  8.2.1 South America Myasthenia Gravis Drugs Sales by Manufacturers (2016-2017)
  8.2.2 South America Myasthenia Gravis Drugs Revenue by Manufacturers (2016-2017)
8.3 South America Myasthenia Gravis Drugs Sales, Revenue and Market Share by Type (2013-2018)
  8.3.1 South America Myasthenia Gravis Drugs Sales and Sales Share by Type (2013-2018)
  8.3.2 South America Myasthenia Gravis Drugs Revenue and Revenue Share by Type (2013-2018)
8.4 South America Myasthenia Gravis Drugs Sales, Revenue and Market Share by Application (2013-2018)
  8.4.1 South America Myasthenia Gravis Drugs Sales and Sales Share by Application (2013-2018)
  8.4.2 South America Myasthenia Gravis Drugs Revenue and Revenue Share by Application (2013-2018)

9 MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS DRUGS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS

9.1 Middle East and Africa Myasthenia Gravis Drugs Sales, Revenue and Market Share by Countries
  9.1.1 Middle East and Africa Myasthenia Gravis Drugs Sales by Countries (2013-2018)
  9.1.2 Middle East and Africa Myasthenia Gravis Drugs Revenue by Countries (2013-2018)
  9.1.3 Saudi Arabia Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
  9.1.4 UAE Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
  9.1.5 Egypt Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
  9.1.6 Nigeria Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
  9.1.7 South Africa Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
9.2 Middle East and Africa Myasthenia Gravis Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
  9.2.1 Middle East and Africa Myasthenia Gravis Drugs Sales by Manufacturers (2016-2017)
  9.2.2 Middle East and Africa Myasthenia Gravis Drugs Revenue by Manufacturers (2016-2017)
9.3 Middle East and Africa Myasthenia Gravis Drugs Sales, Revenue and Market Share by Type (2013-2018)
  9.3.1 Middle East and Africa Myasthenia Gravis Drugs Sales and Sales Share by Type (2013-2018)
  9.3.1 Middle East and Africa Myasthenia Gravis Drugs Revenue and Revenue Share by Type (2013-2018)
9.4 Middle East and Africa Myasthenia Gravis Drugs Sales, Revenue and Market Share by Application (2013-2018)
  9.4.1 Middle East and Africa Myasthenia Gravis Drugs Sales and Sales Share by Application (2013-2018)
  9.4.2 Middle East and Africa Myasthenia Gravis Drugs Revenue and Revenue Share by Application (2013-2018)

10 GLOBAL MYASTHENIA GRAVIS DRUGS MARKET SEGMENT BY TYPE

10.1 Global Myasthenia Gravis Drugs Sales, Revenue and Market Share by Type (2013-2018)
  10.1.1 Global Myasthenia Gravis Drugs Sales and Market Share by Type (2013-2018)
  10.1.2 Global Myasthenia Gravis Drugs Revenue and Market Share by Type (2013-2018)
10.2 Anticholinesterases Sales Growth and Price
  10.2.1 Global Anticholinesterases Sales Growth (2013-2018)
  10.2.2 Global Anticholinesterases Price (2013-2018)
10.3 Immunosuppressants Sales Growth and Price
  10.3.1 Global Immunosuppressants Sales Growth (2013-2018)
  10.3.2 Global Immunosuppressants Price (2013-2018)
10.4 Intravenous Immune Globulins Sales Growth and Price
  10.4.1 Global Intravenous Immune Globulins Sales Growth (2013-2018)
  10.4.2 Global Intravenous Immune Globulins Price (2013-2018)

11 GLOBAL MYASTHENIA GRAVIS DRUGS MARKET SEGMENT BY APPLICATION

11.1 Global Myasthenia Gravis Drugs Sales Market Share by Application (2013-2018)
11.2 Hospitals Sales Growth (2013-2018)
11.3 Clinics Sales Growth (2013-2018)

12 MYASTHENIA GRAVIS DRUGS MARKET FORECAST (2018-2023)

12.1 Global Myasthenia Gravis Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Myasthenia Gravis Drugs Market Forecast by Regions (2018-2023)
  12.2.1 North America Myasthenia Gravis Drugs Market Forecast (2018-2023)
  12.2.2 Europe Myasthenia Gravis Drugs Market Forecast (2018-2023)
  12.2.3 Asia-Pacific Myasthenia Gravis Drugs Market Forecast (2018-2023)
  12.2.4 South America Myasthenia Gravis Drugs Market Forecast (2018-2023)
  12.2.5 Middle East and Africa Myasthenia Gravis Drugs Market Forecast (2018-2023)
12.3 Myasthenia Gravis Drugs Market Forecast by Type (2018-2023)
  12.3.1 Global Myasthenia Gravis Drugs Sales Forecast by Type (2018-2023)
  12.3.2 Global Myasthenia Gravis Drugs Market Share Forecast by Type (2018-2023)
12.4 Myasthenia Gravis Drugs Market Forecast by Application (2018-2023)
  12.4.1 Global Myasthenia Gravis Drugs Sales Forecast by Application (2018-2023)
  12.4.2 Global Myasthenia Gravis Drugs Market Share Forecast by Application (2018-2023)

13 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS

13.1 Sales Channel
  13.1.1 Direct Marketing
  13.1.2 Indirect Marketing
  13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers

14 RESEARCH FINDINGS AND CONCLUSION

15 APPENDIX

15.1 Methodology
15.2 Data Source

List Of Tables

LIST OF TABLES AND FIGURES

Figure Myasthenia Gravis Drugs Picture
Table Product Specifications of Myasthenia Gravis Drugs
Figure Global Myasthenia Gravis Drugs CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (USD Mill